Rachelle Suzanne Jacques
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Akari Therapeutics Files New Patent Application. Akari Therapeutics has submitted a new patent application to expand its intellectual property portfolio. This move is relevant as it aims to strengthen the company's long-term position in its therapeutic areas. The stock currently trades well below its 52-week high, reflecting the significant volatility seen in the sector.
Transaction History
| QURE | ▼ Sell | Open Market | 1,993 | $54K | 6/11/2026 | View on chart |
| QURE | ▲ Buy | Grant | 7,550 | $0 | 6/10/2026 | View on chart |
| CRBP | ▲ Buy | Grant | 3,800 | $0 | 5/19/2026 | View on chart |
| QURE | ▼ Sell | Open Market | 2,112 | $31K | 6/20/2025 | View on chart |
| QURE | ▲ Buy | Grant | 7,970 | $0 | 6/11/2025 | View on chart |
| CRBP | ▲ Buy | Grant | 4,800 | $0 | 5/30/2025 | View on chart |
| QURE | ▲ Buy | Grant | 8,080 | $0 | 6/19/2024 | View on chart |
| QURE | ▼ Sell | Open Market | 2,221 | $11K | 6/13/2024 | View on chart |
| CRBP | ▲ Buy | Grant | 2,783 | $0 | 5/30/2024 | View on chart |
| AKTX | ▲ Buy | Grant | 479,569,892 | $0 | 4/26/2024 | View on chart |
| QURE | ▼ Sell | Open Market | 2,301 | $43K | 6/16/2023 | View on chart |
| QURE | ▲ Buy | Grant | 8,700 | $0 | 6/13/2023 | View on chart |
| QURE | ▼ Sell | Open Market | 384 | $8K | 2/27/2023 | View on chart |
| QURE | ▲ Buy | Grant | 9,080 | $0 | 6/15/2022 | View on chart |
| QURE | ▲ Buy | Grant | 1,534 | $0 | 2/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
QURE shares fall after Huntington data update and Barclays downgrade
Cedar Grove Capital released its Q3 2026 portfolio update, noting QURE holdings. The stock fell 5.9% after Huntington's gene therapy data was updated, prompting a Barclays downgrade to equal‑weight and a new price target of $28. The move comes amid a broader market pullback, with the shares near a 17.1 RSI and a support level of $44.06.
QURE shares fall after Huntington data update and Barclays downgrade. Cedar Grove Capital released its Q3 2026 portfolio update, noting QURE holdings. The stock fell 5.9% after Huntington's gene therapy data was updated, prompting a Barclays downgrade to equal‑weight and a new price target of $28. The move comes amid a broader market pullback, with the shares near a 17.1 RSI and a support level of $44.06.